Rafael pharmaceuticals to present pancreatic & biliary tract cancer data on cpi-613® (devimistat) from its multicenter, randomized phase 1b/2 trials at the 2021 european society of medical oncology world gastrointestinal (gi) congress

Cranbury, n.j., june 30, 2021 (globe newswire) -- rafael pharmaceuticals, inc. (“rafael” or the “company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that data on its lead compound, devimistat, has been selected for an oral presentation at the 2021 european society of medical oncology world gastrointestinal congress (esmo), taking place june 30 through july 3, 2021.
RFL Ratings Summary
RFL Quant Ranking